EGFR and hepatocellular carcinoma: In contrast, the inhibitor of EGFR/MET could down-regulate the Ras/MAPK pathway in HCC cell lines with high phosphorylation of EGFR/MET instead of a condition of low phosphorylation of EGFR/MET.